Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders
This vial clears the 45 threshold on its own, so UK Royal Mail Tracked 24 delivery is free
12 The trial was powered to test noninferiority of semaglutide versus placebo on cardiovascular outcomes for the purpose of regulatory approval
Send download link to: Bring GLP-1 Expertise to Your Practice Are you looking to build or strengthen a weight management or GLP-1 program in your practice
The first trial that tested a GLP-1 in a population with a mood disorder was published in January 2026 by Badulescu et al in Canada, to see if semaglutide (Ozempic) was a viable treatment of cognitive dysfunction in major depressive disorder (MDD), using 72 participants over the course of 16 weeks
Methods Data is collected at three time points: baseline as a socket user, 6 months after surgery (following intensive rehabilitation), and 12 months after surgery
